Quotes 5-day view Real-time Euronext Growth Paris
02/25/2021
02/26/2021
03/01/2021
03/02/2021
03/03/2021
Date
17.94(c)
17.8(c)
18.82(c)
18.62(c)
17.92(c)
Last
150 906
403 217
137 246
87 552
120 342
Volume
-3.76% -0.78% +5.73% -1.06% -3.76% Change
Sales 2020
57,2 M 68,9 M 68,9 M
Net income 2020
-76,7 M -92,5 M -92,5 M
Net cash position 2020
157 M 189 M 189 M
P/E ratio 2020
-6,01x
Yield 2020
-
Sales 2021
66,5 M 80,1 M 80,1 M
Net income 2021
-107 M -129 M -129 M
Net cash position 2021
51,7 M 62,3 M 62,3 M
P/E ratio 2021
-6,34x
Yield 2021
-
Capitalization
771 M 931 M 930 M
EV / Sales 2020
10,7x
EV / Sales 2021
10,8x
Nbr of Employees
259
Free-Float
83,2%
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and...
Notations Surperformance© of Cellectis
Trading Rating : Investor Rating :
News in other languages on CELLECTIS
CELLECTIS - 2020
Is the distribution phase coming to an end ?
BUY
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends CELLECTIS
Short Term Mid-Term Long Term Trends Bearish Neutral Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
2
Average target price
27,35 €
Last Close Price
17,92 €
Spread / Highest target
62,9%
Spread / Average Target
52,6%
Spread / Lowest Target
42,3%
Please enable JavaScript in your browser's settings to use dynamic charts.
1st jan. Capitalization (M$)
CELLECTIS -26.56% 967
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
